argenx, the llama antibodies developer looking to treat severe autoimmune diseases and cancer, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed registered public offering of its ordinary shares in the United States.

The timing, number of ordinary shares and price of the proposed offering have not yet been determined.

More news on Argenx